Diabetic Neuropathic Pain Market Report and Forecast 2025-2034
Description
The diabetic neuropathic pain market was valued at USD 3.30 Billion in 2024 , driven by the increasing prevalence of diabetes across the 8 major markets. The market is expected to grow at a CAGR of 7.72% during the forecast period of 2025-2034, with the values likely to reach USD 6.94 Billion by 2034 .
Diabetic Neuropathic Pain Market Overview
Diabetic neuropathic pain occurs as a result of nerve damage in an individual suffering from diabetes. The pain from diabetic neuropathy can range from tingling in the toes or minor discomfort to severe and sharp pain. The damage to the nerves, primarily in the legs and feet, is caused by the high blood sugar levels in the diabetic patient’s body. Around 20 million Americans are reported to suffer from diabetic neuropathic pain. The increasing prevalence of diabetes is a significant factor driving the demand for effective treatments for the condition. The market growth is also supported by the rising introduction of new medications for targeted pain relief such as serotonin and norepinephrine reuptake inhibitors (SNRIs), anticonvulsants, and topical treatments. Additionally, the growing awareness among patients about diabetic neuropathic pain and the rise in drug approvals by regulatory agencies are anticipated to fuel the market growth.
Diabetic Neuropathic Pain Market Growth Drivers
Increasing Prevalence of Diabetes Drives Market Growth
According to the IDF Diabetes Atlas, 1 in 8 adults, or roughly 783 million individuals are projected to be living with diabetes by 2045, due to factors such as rapid urbanization, a growing aging population, sedentary lifestyle patterns, and rising obesity rates. Diabetic neuropathy is considered the most common complication of diabetes mellitus. It affects around 50% of patients with type 1 and type 2 diabetes mellitus. Thus, the rising number of cases of diabetes is one of the primary drivers of the market for diabetic neuropathic pain, propelling the demand for effective treatment options and advanced pain management therapies.
Diabetic Neuropathic Pain Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rise in Regulatory Approvals of Innovative Treatments to Affect the Market Landscape Significantly
In January 2024, Neuralace Medical, Inc., a startup medical technology company specializing in non-invasive chronic pain relief devices announced the US Food and Drug Administration (FDA) approval of its Axon Therapy, becoming the first-ever FDA-cleared non-invasive, magnetic peripheral nerve stimulation (mPNS) treatment for patients with painful diabetic neuropathy. The rise in regulatory approvals of such innovative, patient-centered, non-invasive solutions is expected to bolster the market growth in the forecast period.
Increased Clinical Research Poised to Augment Diabetic Neuropathic Pain Market Demand
In March 2024, researchers at the UT Southwestern Medical Center conducted a randomized control trial which showed that surgical nerve decompression, which is often used to treat carpal tunnel syndrome and sciatica, might be effective for patients with diabetic peripheral neuropathy. The research study indicated that nerve decompression surgery can release compressed nerves from the surrounding tissue, which can help in offering lasting pain relief to the affected individuals. The growth in such clinical studies to likely to augment the market demand.
Rising Adoption of Non-Opioid Pain Management to Elevate the Diabetic Neuropathic Pain Market Value
A major market trend is the growing preference for non-opioid pain management options such as non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants, and topical treatments. Moreover, the patients are also seeking alternative therapies, such as acupuncture, spinal cord stimulation, and transcutaneous electrical nerve stimulation (TENS), which is likely to impact the market dynamics positively.
Shift Towards Multimodal Pain Management to Boost Diabetic Neuropathic Pain Market Size
One of the significant market trends is the growing use of combination therapies for the effective management of diabetic neuropathic pain. The patients are increasingly prescribed different pharmacological treatments to improve pain relief and reduce side effects. In addition, non-pharmacological methods are also being integrated with traditional drug therapies to enhance clinical benefits.
Diabetic Neuropathic Pain Market Segmentation
Diabetic Neuropathic Pain Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
The Peripheral Neuropathy Segment Based on Type Holds a Significant Market Share
The market segmentation by type includes peripheral neuropathy, autonomic neuropathy, proximal neuropathy, focal neuropathy, and others. Peripheral neuropathy ranks as the most common form of diabetic neuropathy. The condition impacts the peripheral nerves (usually legs and feet) and causes symptoms such as burning sensations, tingling, and sharp pain. The high demand for treatments for peripheral neuropathy, including medications such as anticonvulsants, antidepressants, and topical agents, is propelling the growth of the segment.
Diabetic Neuropathic Pain Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States represents one of the largest markets for diabetic neuropathic pain due to the high prevalence of diabetes and the strong presence of major pharmaceutical companies. The growing demand for innovative therapies in the region, including both pharmacological treatments and non-pharmacological options (such as neuromodulation devices) is driving market growth. Moreover, the rising patient awareness regarding early diagnosis and management of diabetic neuropathy is expected to elevate the market value in the country in the coming years.
Leading Players in the Diabetic Neuropathic Pain Market
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Pfizer, Inc.
Pharmaceutical industry company Pfizer Inc., headquartered in New York, United States, has a prominent presence in the market and is known for its robust portfolio of medications for pain management and neurological disorders. Pfizer's LYRICA® CR (pregabalin ) extended-release tablets CV is a once-daily FDA-cleared therapy indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy.
NeuroMetrix, Inc.
NeuroMetrix, Inc., based in Massachusetts, United States, is a spinoff of the Harvard-MIT Division of Health Sciences and Technology. This commercial-stage neurotechnology company is engaged in developing and marketing products that detect, diagnose, and monitor peripheral nerve and spinal cord disorders including diabetic neuropathy.
GSK plc
GSK plc, a British multinational pharmaceutical and biotechnology company, is one of the leading players in the market. The company is known for its extensive research capabilities and a wide range of neurological and pain management products. GSK-3858279, an immunomodulatory monoclonal antibody that targets CCL17, is under clinical development for the treatment of diabetic neuropathic pain.
Johnson & Johnson
Johnson & Johnson, headquartered in New Brunswick, New Jersey, plays a significant role in the growth of the market. One of the key products of Johnson & Johnson Innovative Medicine is an oral analgesic NUCYNTA® ER (tapentadol) extended-release tablets for the management of diabetic neuropathy pain.
Other key players in the market include Lupin, Astellas Pharma, Eli Lilly and Company, Glenmark, Sun Pharmaceuticals Ltd, and Abbott.
Key Questions Answered in the Diabetic Neuropathic Pain Market Report
Diabetic Neuropathic Pain Market Overview
Diabetic neuropathic pain occurs as a result of nerve damage in an individual suffering from diabetes. The pain from diabetic neuropathy can range from tingling in the toes or minor discomfort to severe and sharp pain. The damage to the nerves, primarily in the legs and feet, is caused by the high blood sugar levels in the diabetic patient’s body. Around 20 million Americans are reported to suffer from diabetic neuropathic pain. The increasing prevalence of diabetes is a significant factor driving the demand for effective treatments for the condition. The market growth is also supported by the rising introduction of new medications for targeted pain relief such as serotonin and norepinephrine reuptake inhibitors (SNRIs), anticonvulsants, and topical treatments. Additionally, the growing awareness among patients about diabetic neuropathic pain and the rise in drug approvals by regulatory agencies are anticipated to fuel the market growth.
Diabetic Neuropathic Pain Market Growth Drivers
Increasing Prevalence of Diabetes Drives Market Growth
According to the IDF Diabetes Atlas, 1 in 8 adults, or roughly 783 million individuals are projected to be living with diabetes by 2045, due to factors such as rapid urbanization, a growing aging population, sedentary lifestyle patterns, and rising obesity rates. Diabetic neuropathy is considered the most common complication of diabetes mellitus. It affects around 50% of patients with type 1 and type 2 diabetes mellitus. Thus, the rising number of cases of diabetes is one of the primary drivers of the market for diabetic neuropathic pain, propelling the demand for effective treatment options and advanced pain management therapies.
Diabetic Neuropathic Pain Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rise in Regulatory Approvals of Innovative Treatments to Affect the Market Landscape Significantly
In January 2024, Neuralace Medical, Inc., a startup medical technology company specializing in non-invasive chronic pain relief devices announced the US Food and Drug Administration (FDA) approval of its Axon Therapy, becoming the first-ever FDA-cleared non-invasive, magnetic peripheral nerve stimulation (mPNS) treatment for patients with painful diabetic neuropathy. The rise in regulatory approvals of such innovative, patient-centered, non-invasive solutions is expected to bolster the market growth in the forecast period.
Increased Clinical Research Poised to Augment Diabetic Neuropathic Pain Market Demand
In March 2024, researchers at the UT Southwestern Medical Center conducted a randomized control trial which showed that surgical nerve decompression, which is often used to treat carpal tunnel syndrome and sciatica, might be effective for patients with diabetic peripheral neuropathy. The research study indicated that nerve decompression surgery can release compressed nerves from the surrounding tissue, which can help in offering lasting pain relief to the affected individuals. The growth in such clinical studies to likely to augment the market demand.
Rising Adoption of Non-Opioid Pain Management to Elevate the Diabetic Neuropathic Pain Market Value
A major market trend is the growing preference for non-opioid pain management options such as non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants, and topical treatments. Moreover, the patients are also seeking alternative therapies, such as acupuncture, spinal cord stimulation, and transcutaneous electrical nerve stimulation (TENS), which is likely to impact the market dynamics positively.
Shift Towards Multimodal Pain Management to Boost Diabetic Neuropathic Pain Market Size
One of the significant market trends is the growing use of combination therapies for the effective management of diabetic neuropathic pain. The patients are increasingly prescribed different pharmacological treatments to improve pain relief and reduce side effects. In addition, non-pharmacological methods are also being integrated with traditional drug therapies to enhance clinical benefits.
Diabetic Neuropathic Pain Market Segmentation
Diabetic Neuropathic Pain Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Peripheral Neuropathy
- Autonomic Neuropathy
- Proximal Neuropathy
- Focal Neuropathy
- Others
- Drugs
- Analgesics
- NSAIDs
- Antidepressants
- Anticonvulsant Drugs
- Others
- Radiotherapy
- Others
- Oral
- Parenteral
- Others
- Hospitals & Clinics
- Specialty Centers
- Homecare Settings
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- India
- Japan
The Peripheral Neuropathy Segment Based on Type Holds a Significant Market Share
The market segmentation by type includes peripheral neuropathy, autonomic neuropathy, proximal neuropathy, focal neuropathy, and others. Peripheral neuropathy ranks as the most common form of diabetic neuropathy. The condition impacts the peripheral nerves (usually legs and feet) and causes symptoms such as burning sensations, tingling, and sharp pain. The high demand for treatments for peripheral neuropathy, including medications such as anticonvulsants, antidepressants, and topical agents, is propelling the growth of the segment.
Diabetic Neuropathic Pain Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States represents one of the largest markets for diabetic neuropathic pain due to the high prevalence of diabetes and the strong presence of major pharmaceutical companies. The growing demand for innovative therapies in the region, including both pharmacological treatments and non-pharmacological options (such as neuromodulation devices) is driving market growth. Moreover, the rising patient awareness regarding early diagnosis and management of diabetic neuropathy is expected to elevate the market value in the country in the coming years.
Leading Players in the Diabetic Neuropathic Pain Market
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Pfizer, Inc.
Pharmaceutical industry company Pfizer Inc., headquartered in New York, United States, has a prominent presence in the market and is known for its robust portfolio of medications for pain management and neurological disorders. Pfizer's LYRICA® CR (pregabalin ) extended-release tablets CV is a once-daily FDA-cleared therapy indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy.
NeuroMetrix, Inc.
NeuroMetrix, Inc., based in Massachusetts, United States, is a spinoff of the Harvard-MIT Division of Health Sciences and Technology. This commercial-stage neurotechnology company is engaged in developing and marketing products that detect, diagnose, and monitor peripheral nerve and spinal cord disorders including diabetic neuropathy.
GSK plc
GSK plc, a British multinational pharmaceutical and biotechnology company, is one of the leading players in the market. The company is known for its extensive research capabilities and a wide range of neurological and pain management products. GSK-3858279, an immunomodulatory monoclonal antibody that targets CCL17, is under clinical development for the treatment of diabetic neuropathic pain.
Johnson & Johnson
Johnson & Johnson, headquartered in New Brunswick, New Jersey, plays a significant role in the growth of the market. One of the key products of Johnson & Johnson Innovative Medicine is an oral analgesic NUCYNTA® ER (tapentadol) extended-release tablets for the management of diabetic neuropathy pain.
Other key players in the market include Lupin, Astellas Pharma, Eli Lilly and Company, Glenmark, Sun Pharmaceuticals Ltd, and Abbott.
Key Questions Answered in the Diabetic Neuropathic Pain Market Report
- What was the diabetic neuropathic pain market value in 2024?
- What is the diabetic neuropathic pain market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on the type?
- What is the market breakup based on treatment?
- What is the market breakup by the route of administration?
- Who are the major end users in the market?
- What are the major factors aiding the diabetic neuropathic pain market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How do the prevalence and incidence of diabetes affect the market landscape?
- What are the major diabetic neuropathic pain market trends?
- How does the rise in the geriatric population impact the market size?
- Which disorder will dominate the market share?
- Which treatment is expected to have a high market value in the coming years?
- Which route of administration will experience the highest demand in the market segment?
- Which end user is projected to contribute to the highest market growth?
- Who are the key players involved in the diabetic neuropathic pain market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Diabetic Neuropathic Pain Market Overview – 8 Major Markets
- 3.1 Diabetic Neuropathic Pain Market Historical Value (2018-2024)
- 3.2 Diabetic Neuropathic Pain Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Diabetic Neuropathic Pain Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Diabetic Neuropathic Pain Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Diabetic Neuropathic Pain Market Landscape – 8 Major Markets
- 8.1 Diabetic Neuropathic Pain Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Diabetic Neuropathic Pain Market: Product Landscape
- 8.2.1 Analysis by Treatment
- 8.2.2 Analysis by Route of Administration
- 9 Diabetic Neuropathic Pain Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Diabetic Neuropathic Pain Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Diabetic Neuropathic Pain Market Segmentation (218-2034) - 8 Major Markets
- 12.1 Diabetic Neuropathic Pain Market (2018-2034) by Type
- 12.1.1 Market Overview
- 12.1.2 Peripheral Neuropathy
- 12.1.3 Autonomic Neuropathy
- 12.1.4 Proximal Neuropathy
- 12.1.5 Focal Neuropathy
- 12.1.6 Others
- 12.2 Diabetic Neuropathic Pain Market (2018-2034) by Treatment
- 12.2.1 Market Overview
- 12.2.2 Drugs
- 12.2.2.1 Analgesics
- 12.2.2.2 NSAIDs
- 12.2.2.3 Antidepressants
- 12.2.2.4 Anticonvulsant Drugs
- 12.2.2.5 Others
- 12.2.3 Radiotherapy
- 12.2.4 Others
- 12.3 Diabetic Neuropathic Pain Market (2018-2034) by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Oral
- 12.3.3 Parenteral
- 12.3.4 Others
- 12.4 Diabetic Neuropathic Pain Market (2018-2034) by End User
- 12.4.1 Market Overview
- 12.4.2 Hospitals & Clinics
- 12.4.3 Specialty Centers
- 12.4.4 Homecare Settings
- 12.4.5 Others
- 12.5 Diabetic Neuropathic Pain Market (2018-2034) by Region
- 12.5.1 Market Overview
- 12.5.2 United States
- 12.5.3 EU-4 and the United Kingdom
- 12.5.3.1 Germany
- 12.5.3.2 France
- 12.5.3.3 Italy
- 12.5.3.4 Spain
- 12.5.3.5 United Kingdom
- 12.5.4 Japan
- 12.5.5 India
- 13 United States Diabetic Neuropathic Pain Market (218-2034)
- 13.1 United States Diabetic Neuropathic Pain Market Historical Value (2018-2024)
- 13.2 United States Diabetic Neuropathic Pain Market Forecast Value (2025-2034)
- 13.3 United States Diabetic Neuropathic Pain Market (2018-2034) by Type
- 13.3.1 Market Overview
- 13.3.2 Peripheral Neuropathy
- 13.3.3 Autonomic Neuropathy
- 13.3.4 Proximal Neuropathy
- 13.3.5 Focal Neuropathy
- 13.3.6 Others
- 13.4 United States Diabetic Neuropathic Pain Market (2018-2034) by Treatment
- 13.4.1 Market Overview
- 13.4.2 Drugs
- 13.4.2.1 Analgesics
- 13.4.2.2 NSAIDs
- 13.4.2.3 Antidepressants
- 13.4.2.4 Anticonvulsant Drugs
- 13.4.2.5 Others
- 13.4.3 Radiotherapy
- 13.4.4 Others
- 13.5 United States Diabetic Neuropathic Pain Market (2018-2034) by Route of Administration
- 13.5.1 Market Overview
- 13.5.2 Oral
- 13.5.3 Parenteral
- 13.5.4 Others
- 13.6 United States Diabetic Neuropathic Pain Market (2018-2034) by End User
- 13.6.1 Market Overview
- 13.6.2 Hospitals & Clinics
- 13.6.3 Specialty Centers
- 13.6.4 Homecare Settings
- 13.6.5 Others
- 14 EU-4 and United Kingdom Diabetic Neuropathic Pain Market (218-2034)
- 14.1 EU-4 and United Kingdom Diabetic Neuropathic Pain Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Diabetic Neuropathic Pain Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Diabetic Neuropathic Pain Market (2018-2034) by Type
- 14.3.1 Market Overview
- 14.3.2 Peripheral Neuropathy
- 14.3.3 Autonomic Neuropathy
- 14.3.4 Proximal Neuropathy
- 14.3.5 Focal Neuropathy
- 14.3.6 Others
- 14.4 EU-4 and United Kingdom Diabetic Neuropathic Pain Market (2018-2034) by Treatment
- 14.4.1 Market Overview
- 14.4.2 Drugs
- 14.4.2.1 Analgesics
- 14.4.2.2 NSAIDs
- 14.4.2.3 Antidepressants
- 14.4.2.4 Anticonvulsant Drugs
- 14.4.2.5 Others
- 14.4.3 Radiotherapy
- 14.4.4 Others
- 14.5 EU-4 and United Kingdom Diabetic Neuropathic Pain Market (2018-2034) by Route of Administration
- 14.5.1 Market Overview
- 14.5.2 Oral
- 14.5.3 Parenteral
- 14.5.4 Others
- 14.6 EU-4 and United Kingdom Diabetic Neuropathic Pain Market (2018-2034) by End User
- 14.6.1 Market Overview
- 14.6.2 Hospitals & Clinics
- 14.6.3 Specialty Centers
- 14.6.4 Homecare Settings
- 14.6.5 Others
- 15 Japan Diabetic Neuropathic Pain Market
- 15.1 Japan Diabetic Neuropathic Pain Market Historical Value (2018-2024)
- 15.2 Japan Diabetic Neuropathic Pain Market Forecast Value (2025-2034)
- 15.3 Japan Diabetic Neuropathic Pain Market (2018-2034) by Type
- 15.3.1 Market Overview
- 15.3.2 Peripheral Neuropathy
- 15.3.3 Autonomic Neuropathy
- 15.3.4 Proximal Neuropathy
- 15.3.5 Focal Neuropathy
- 15.3.6 Others
- 15.4 Japan Diabetic Neuropathic Pain Market (2018-2034) by Treatment
- 15.4.1 Market Overview
- 15.4.2 Drugs
- 15.4.2.1 Analgesics
- 15.4.2.2 NSAIDs
- 15.4.2.3 Antidepressants
- 15.4.2.4 Anticonvulsant Drugs
- 15.4.2.5 Others
- 15.4.3 Radiotherapy
- 15.4.4 Others
- 15.5 Japan Diabetic Neuropathic Pain Market (2018-2034) by Route of Administration
- 15.5.1 Market Overview
- 15.5.2 Oral
- 15.5.3 Parenteral
- 15.5.4 Others
- 15.6 Japan Diabetic Neuropathic Pain Market (2018-2034) by End User
- 15.6.1 Market Overview
- 15.6.2 Hospitals & Clinics
- 15.6.3 Specialty Centers
- 15.6.4 Homecare Settings
- 15.6.5 Others
- 16 India Diabetic Neuropathic Pain Market
- 16.1 India Diabetic Neuropathic Pain Market Historical Value (2018-2024)
- 16.2 India Diabetic Neuropathic Pain Market Forecast Value (2025-2034)
- 16.3 India Diabetic Neuropathic Pain Market (2018-2034) by Type
- 16.3.1 Market Overview
- 16.3.2 Peripheral Neuropathy
- 16.3.3 Autonomic Neuropathy
- 16.3.4 Proximal Neuropathy
- 16.3.5 Focal Neuropathy
- 16.3.6 Others
- 16.4 India Diabetic Neuropathic Pain Market (2018-2034) by Treatment
- 16.4.1 Market Overview
- 16.4.2 Drugs
- 16.4.2.1 Analgesics
- 16.4.2.2 NSAIDs
- 16.4.2.3 Antidepressants
- 16.4.2.4 Anticonvulsant Drugs
- 16.4.2.5 Others
- 16.4.3 Radiotherapy
- 16.4.4 Others
- 16.5 India Diabetic Neuropathic Pain Market (2018-2034) by Route of Administration
- 16.5.1 Market Overview
- 16.5.2 Oral
- 16.5.3 Parenteral
- 16.5.4 Others
- 16.6 India Diabetic Neuropathic Pain Market (2018-2034) by End User
- 16.6.1 Market Overview
- 16.6.2 Hospitals & Clinics
- 16.6.3 Specialty Centers
- 16.6.4 Homecare Settings
- 16.6.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 Japan PMDA
- 17.5 India CDSCO
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grants Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Application
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by NIH Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Treatment Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Treatment Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share Analysis, By Region (Top 5 Companies)
- 23.2 Pfizer , Inc.
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Companies News and Developments
- 23.2.5 Certifications
- 23.3 NeuroMetrix, Inc.
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Companies News and Developments
- 23.3.5 Certifications
- 23.4 GSK plc
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Companies News and Developments
- 23.4.5 Certifications
- 23.5 Johnson & Johnson
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Companies News and Developments
- 23.5.5 Certifications
- 23.6 Lupin
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Companies News and Developments
- 23.6.5 Certifications
- 23.7 Astellas Pharma
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Companies News and Developments
- 23.7.5 Certifications
- 23.8 Eli Lily and Company
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Companies News and Developments
- 23.8.5 Certifications
- 23.9 Glenmark
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Companies News and Developments
- 23.9.5 Certifications
- 23.10 Sun Pharmaceuticals Ltd
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Companies News and Developments
- 23.10.5 Certifications
- 23.11 Abbott
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Companies News and Developments
- 23.11.5 Certifications
- 24 Diabetic Neuropathic Pain Treatment Drugs - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
